Company Active LTD

Company profile

Cyted Ltd

UK company 11478299, incorporated on 23 July 2018.

The Data-Driven Diagnostics Company | Cyted

Our unique approach combines expertise in gastrointestinal oncology, digital pathology and AI-driven biomarker discovery.

Company number

11478299

Incorporated

23 Jul 2018

Companies House status

Active

Company identity

Founded / incorporated

23 July 2018

Company number 11478299

Verify at Companies House

Legal name

CYTED LTD

Company type

LTD

Region

East of England

Registered address

Unknown

Insolvency history

No

Corporate ownership

Updated 07 Jul 2026 09:49

6 levels 4 ultimate controllers Controls 1

1

Company Active LTD

Cyted Ltd

CRN 11478299

2

Direct controller Active LTD

BGF Investment Management Limited

CRN 10608481

3

Intermediate controller Active PLC

BGF Group PLC

CRN 10657226

4

Intermediate controller Active LTD

Barclays Funds Investments Limited

CRN 04002470

5

Intermediate controller Active LTD

HSBC (BGF) Investments Limited

CRN 05229587

6

Intermediate controller Active LTD

RBS Sme Investments Limited

CRN 06838433

7

Intermediate controller Active LTD

Uberior Investments Limited

CRN SC073998

8

Intermediate controller Active PLC

HSBC Bank PLC

CRN 00014259

9

Intermediate controller Active LTD

LBG Equity Investments Limited

CRN 02412574

10

Intermediate controller Active LTD

Barclays Equity Holdings Limited

CRN 02569002

11

Intermediate controller Active LTD

RBS AA Holdings (UK) Limited

CRN 02717209

12

Ultimate controller Active PLC

HSBC Holdings PLC

CRN 00617987

13

Intermediate controller Active LTD

Barclays Principal Investments Limited

CRN 08116604

14

Ultimate controller Active PLC

Natwest Group PLC

CRN SC045551

15

Ultimate controller Active PLC

Lloyds Banking Group PLC

CRN SC095000

16

Ultimate controller Active PLC

Barclays PLC

CRN 00048839

Company events

Reference milestones and recent Companies House filing stream events.

4 events

31 Jul

2026

Confirmation Statement With Updates

Confirmation-statement

CS01 | Transaction MzUzNjM1NTEwNmFkaXF6a2N4

Published 31 Jul 2026 16:08

29 Jul

2026

Change To A Person With Significant Control

Persons-with-significant-control

PSC04 | Transaction MzUzNTc1NDY5MmFkaXF6a2N4

Published 29 Jul 2026 09:37

29 Jul

2026

Change To A Person With Significant Control

Persons-with-significant-control

PSC04 | Transaction MzUzNTc1NDY4OGFkaXF6a2N4

Published 29 Jul 2026 09:37

23 Jul

2018

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards

First funded

2020

Funded years

2020, 2024

Age at first award

1 years

Projects

2024 Collaborative R&D Lead participant

QuBIE: Quantitative Biomarker Identification for Non-Endoscopic Prediction and Monitoring of Treatment Response in Eosinophilic Oesophagitis

1 Jan 2024 to 30 Jun 2025

Awarded

£398,284

Total cost £663,806

Eosinophilic oesophagitis (EoE) is a disease of the oesophagus ("food pipe") affecting tens of thousands of adults and children across the UK. Related to asthma, allergies and other chronic inflammatory conditions, this disease has been on the rise in the last decade. However, it can often take years and even several trips to A&E due to food getting stuck...

2020 Collaborative R&D

Project DELTA - integrateD diagnostic solution for EarLy deTection of oesophageal cAncer

1 Feb 2020 to 30 Apr 2023

Awarded

£1,062,858

Total cost £1,518,369

N/A

Product types

Collaborative R&D